OBJECTIVE: To examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response. METHODS: We screened 224 subjects (52% female, mean age 39 ± 11 years) with SCID-diagnosed major depressive disorder (MDD), and obtained 194 genetic samples. 49 subjects (49% female, mean age 36 ± 11 years) participated in a 12-week open clinical trial of fluoxetine 20-60 mg/day. Association between clinical response and C677T and A2756G polymorphisms, folate, B12, and homocysteine was examined. RESULTS: Prevalence of the C677T and A2756G polymorphisms was consistent with previous reports (C/C = 41%, C/T = 47%, T/T = 11%, A/A = 66%, A/G = 29%, G/G = 4%). In the fluoxetine-treated subsample (n = 49), intent-to-treat (ITT) response rates were 47% for C/C subjects and 46% for pooled C/T and T/T subjects (nonsignificant). ITT response rates were 38% for A/A subjects and 60% for A/G subjects (nonsignificant), with no subjects exhibiting the G/G homozygote. Mean baseline plasma B12 was significantly lower in A/G subjects compared to A/A, but folate and homocysteine levels were not affected by genetic status. Plasma folate was negatively associated with treatment response. CONCLUSION: The C677T and A2756G polymorphisms did not significantly affect antidepressant response. These preliminary findings require replication in larger samples.
OBJECTIVE: To examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response. METHODS: We screened 224 subjects (52% female, mean age 39 ± 11 years) with SCID-diagnosed major depressive disorder (MDD), and obtained 194 genetic samples. 49 subjects (49% female, mean age 36 ± 11 years) participated in a 12-week open clinical trial of fluoxetine 20-60 mg/day. Association between clinical response and C677T and A2756G polymorphisms, folate, B12, and homocysteine was examined. RESULTS: Prevalence of the C677T and A2756G polymorphisms was consistent with previous reports (C/C = 41%, C/T = 47%, T/T = 11%, A/A = 66%, A/G = 29%, G/G = 4%). In the fluoxetine-treated subsample (n = 49), intent-to-treat (ITT) response rates were 47% for C/C subjects and 46% for pooled C/T and T/T subjects (nonsignificant). ITT response rates were 38% for A/A subjects and 60% for A/G subjects (nonsignificant), with no subjects exhibiting the G/G homozygote. Mean baseline plasma B12 was significantly lower in A/G subjects compared to A/A, but folate and homocysteine levels were not affected by genetic status. Plasma folate was negatively associated with treatment response. CONCLUSION: The C677T and A2756G polymorphisms did not significantly affect antidepressant response. These preliminary findings require replication in larger samples.
Authors: Patrick J McGrath; Jonathan W Stewart; Frederic M Quitkin; Ying Chen; Jonathan E Alpert; Andrew A Nierenberg; Maurizio Fava; Jianfeng Cheng; Eva Petkova Journal: Am J Psychiatry Date: 2006-09 Impact factor: 18.112
Authors: Roy H Perlis; Shaun Purcell; Jesen Fagerness; Cristina Cusin; Lesley Yamaki; Maurizio Fava; Jordan W Smoller Journal: Biol Psychiatry Date: 2007-02-14 Impact factor: 13.382
Authors: Helga Refsum; Eha Nurk; A David Smith; Per M Ueland; Clara G Gjesdal; Ingvar Bjelland; Aage Tverdal; Grethe S Tell; Ottar Nygård; Stein E Vollset Journal: J Nutr Date: 2006-06 Impact factor: 4.798
Authors: Christine M Pfeiffer; Clifford L Johnson; Ram B Jain; Elizabeth A Yetley; Mary Frances Picciano; Jeanne I Rader; Kenneth D Fisher; Joseph Mulinare; John D Osterloh Journal: Am J Clin Nutr Date: 2007-09 Impact factor: 7.045
Authors: Hee Ju Kang; Robert Stewart; Kyung Yeol Bae; Sung Wan Kim; Il Seon Shin; Hyuno Kang; Won Jin Moon; Young Joon Hong; Youngkeun Ahn; Myung Ho Jeong; Jin Sang Yoon; Jae Min Kim Journal: Oncotarget Date: 2016-10-18